Introduction
Obesity plays a major role in the pathogenesis of several medical problems, including metabolic and cardiovascular diseases (1) . Abdominal obesity is particularly important because it is more closely related to obesity-related complications than peripheral or subcutaneous fat. It was reported that increased intraabdominal visceral fat is associated with hypertriglyceridemia and hyperinsulinemia. Visceral adipose tissue (VAT) is more active metabolically and is different from subcutaneous fat tissue (SCFT) in the production of adipocytokines that may regulate insulin sensitivity and cause these differences (2, 3) .
One of the mechanisms linking obesity with metabolic and cardiovascular diseases is inflammation. Obesity is a state of chronic low-grade inflammation characterized by elevated concentrations of circulating inflammatory markers such as C-reactive protein (CRP). CRP level is especially high in visceral obesity (4, 5) and it is an indicator of cardiovascular disease risk (6) and diabetes (7) .
Suresh et al. (8) compared SCFT thickness with body mass index (BMI) as a marker for pregnancy outcomes and they suggested that central obesity is a stronger risk factor than general adiposity in pregnancy.
There is a marked increase in plasma levels of cholesterol and triacyl glycerol during pregnancy; however, it is unknown whether maternal VAT or SCFT is associated with these changes or if some other metabolic complications related to visceral-subcutaneous fat thickness are similar in pregnant and nonpregnant women. In addition to this, there might be an association between VAT and/or SCFT thickness and some pregnancy-related complications. Therefore, measurement of visceral-subcutaneous fat during the first trimester might help us to identify risk groups in whom early detection of gestational metabolic disorders (gestational diabetes or hypertension) is essential.
Measurement of visceral or peripheral fat by ultrasound is an easy, noninvasive method and it avoids ionizing radiation. Ultrasound measurement of VAT is also closely correlated with computed tomographyderived measurements (9) . In this study we measured VAT and SCFT thicknesses in pregnant women in their first trimester and compared these values with CRP, HbA1c, lipid, and biochemical parameters.
Materials and methods
This cross-sectional study was done with 90 women attending the Turgut Özal University Faculty of Medicine, Obstetrics and Gynecology Department, Ankara.
Inclusion criteria were: singleton pregnancy with a live embryo, gestational age 6-14 weeks, healthy women without any medical disorders, and regular menses without hormonal contraception.
The exclusion criteria were: smoking or drug use (other than prenatal supplemental vitamins) during the index pregnancy, and a previous history of gestational diabetes or any other systemic disease. Written and informed consent was obtained from all women. Approval for this study was obtained from the local institutional review board of the Faculty of Medicine of Turgut Özal University.
Body weight and height were measured in all cases. BMI was calculated as weight (kg) / height (m 2 ). All measurements were obtained in the morning after overnight fasting.
All ultrasound examinations were performed by the same operator. Gestational age was calculated using a modified Naegele's rule. Last menstrual period-derived gestational age was compared with ultrasound-derived gestational age according to crown-rump length (CRL) (10) . The study was performed with a using an Aloka Prosound SSD-3500SX (Aloka Holding Europe AG, Switzerland) 3.5 MHz transabdominal and 6.5 MHz transvaginal probe.
The technique of Armellini et al. (11) was used to measure SCFT and VAT. SCFT depth was measured from the subcutaneous fat layer to the outer border of the rectus abdominus muscle at the level of the linea alba. VAT was measured from the inner border of the rectus abdominus muscle at the level of the linea alba to the anterior wall of the abdominal aorta. Application of excessive pressure over the abdominal wall was avoided during the measurements.
Venous blood samples were collected in the morning, after overnight fasting, from the brachial vein of the patients. Blood samples were immediately centrifuged, and plasma and serum samples were kept at -70 °C until laboratory testing.
Glucose was measured with a standard hexokinase reference method (Cobas Integra 800 analyzer; Roche Diagnostics, Switzerland).
Total cholesterol, HDL cholesterol, VLDL, BUN, creatinine, gamma-glutamyltransferase (GGT), and triglycerides were measured with an enzymatic color test (Cobas Integra 800 analyzer, Roche Diagnostics). LDL cholesterol was calculated according to the Friedewald formula (12) .
Hemoglobin A1c (HbA1c) was determined by means of high-performance liquid chromatography (Shimadzu, Kyoto, Japan).
C-reactive protein (CRP) levels were measured by nephelometry (Beckman Coulter Image, USA). Pou et al. (13) established the VAT and SCFT correlation index with CRP in women as 0.45. For an α error of 0.05 and β error of 0.05, in order to achieve 95% power, the minimum sample size needed was calculated to be 58.
Statistical analyses
Statistical analyses were conducted using SPSS 15.0 for Windows (SPSS Inc., USA). Descriptive statistics are presented as mean values ± SD and median (interquartile range, IQR). To approximate a normal distribution, logtransformed data on HbA1c and CRP were used in the analysis. The chi-square test was used for comparison of categorical data. Student's t-test was used for comparison of groups with normal distribution. For groups that were not distributed normally, the Mann-Whitney test was used for comparison. Spearman correlation coefficients were used to estimate the correlations between serum CRP, HbA1c, and obesity-related parameters (VAT, SAT, lipid profile, BMI) and clinical characteristics. Backwards multiple linear regression analysis was performed to investigate the relationship between CRP and HbA1c concentration as dependent variables and BMI, SAT, and VAT as independent variables. ROC analysis was done to find the best cut-off point of VAT and SCFT for determination of CRP level. After analysis of frequency for VAT and SCFT, the most appropriate values for grouping patients were found to be 4 cm for VAT and 2 cm for SCFT. Patients were divided into 2 groups according to these values and compared with each other. P < 0.05 was considered to be statistically significant.
Results
A total 90 of patients were enrolled in the study. Six patients were excluded because not all of the blood tests were performed. Demographic data of the remaining 84 cases are presented as means ± SD and median (IQR). Mean age was 27.04 ± 4.60 years, gravida was 2 (IQR: 2), parity was 1 (IQR: 1), and BMI was 22 Cut-off values for VAT and SCFT for the Turkish population, determined by ROC curve analysis, were 4.11 cm and 2.13 cm, respectively. The most suitable and closest values to these thresholds were taken as cut-off points (4 cm for VAT and 2 cm for SCFT) and patients were divided into 2 groups according to these cut-off points. Distribution of women as below or above 4 cm for VAT and 2 cm for SCFT was calculated. This distribution of groups is shown in Tables 1 and 2. BMI was over 25 kg/m 2 in 16.7% (n = 14) of cases. VAT and SCFT were over the cut-off points (over 4 and 2 cm, respectively) in 32.2% (n = 27) and 40.7% (n = 34) of all cases, respectively. VAT was found to be higher than 4 cm in 100.0% of cases with high BMIs (over 25 kg/m 2 ). Similarly, SCFT was higher than 2 cm in 75% (10) of cases with high BMI.
High CRP (>8 mg/L) and HbA1c (>6%) were found in 17.5% (n = 15) and 7.1% (n = 6) of all cases, respectively. CRP and HbA1c levels were higher than normal in 50.0% (n = 7) and 21.4% (n = 3) of women with high BMIs (over 25 kg/m 2 ). High CRP and HbA1c levels were found in 45.5% (n = 12) and 18.2% (n = 5) of cases with VAT over 4 cm, respectively. In cases with high SCFT (over 2 cm), CRP and HbA1c levels were high in 31.3% (n = 10) and 18.8% (n = 6) of cases, respectively (Tables 1 and 2 ).
For CRP and HbA1c parameters to approximate a normal distribution, log-transformed data on HbA1c and CRP were used in the analysis. Comparison of groups according to VAT thickness (above or below 4 cm) revealed statistically significant differences between them in terms of log CRP and log HbA1c (P = 0.001 and P = 0.009). Similarly significant differences were observed in SCFT subgroups (below or above 2 cm) in terms of log CRP and log HbA1c (P = 0.011 and P = 0.003).
Comparison of VAT subgroups for other parameters revealed no significance except for SCFT thickness, BMI, creatinine, and GGT levels (P < 0.001, P < 0.001, P = 0.005, and P = 0.006). Comparison of SCFT subgroups revealed significant differences between them in terms of gravida and BMI (P = 0.033, P = 0.008), but no difference for other parameters.
Comparison of groups according to BMI revealed that VAT and SCFT thicknesses were significantly higher in women with BMIs over 25 kg/m 2 than in women with lower BMIs (P = 0.011 and P = 0.015). Log CRP was significantly higher in women with BMIs of ≥25 kg/m 2 than in women with BMIs of <25 kg/m 2 (P < 0.001). There was borderline significance between high-and low-BMI women in terms of log HbA1c levels (P = 0.058) ( Table 3) .
Correlation analysis demonstrated that SCFT correlated positively with log CRP and log HbA1c (rho = 0.258, P = 0.021; rho = 0.235, P = 0.032). In addition to a correlation between SCFT and VAT thickness (rho = 0.475, P < 0.001), SCFT had significant relationships with BMI and GGT (rho = 0.581, P < 0.001; rho = 0.293, P = 0.013). VAT also correlated positively with log CRP, log HbA1c, BMI, and GGT (rho = 0.211, P = 0.048; rho = 0.234, P = 0.032; rho = 0.536, P < 0.001; rho = 0.586, P < 0.001).
The best cut-off point for determination of high CRP was 4.11 cm (71.4% and 84.8%) for VAT and 2.13 cm (71.4% and 75.8%) for SCFT (AUC = 0.723, CI: 0.552-0.894, P = 0.009; and AUC = 0.784, CI: 0.656-0.911, P = 0.001, respectively). The best cut-off point for prediction of high HbA1c was 5.37 cm (66.7% and 94.9%) for VAT and 2.17 cm (66.7% and 74.4%) for SCFT (AUC = 0.739, CI: 0.496-0.983, P = 0.052; and AUC = 0.752, CI: 0.657-0.848, P = 0.040, respectively).
Regression analysis was done with log CRP as a dependent variable and obesity-related factors (VAT, SCFT, BMI, lipid profile) as independent variables. As a result, it was found that high serum log CRP and log HbA1c were significantly associated with VAT (P < 0.001). The most important parameter in prediction of high log CRP and log HbA1c was VAT (P = 0.001 and P = 0.021).
Discussion
Many researchers have demonstrated that obesity is a state of chronic low-grade inflammation (5, 14, 15) . Inflammation itself may be the cause of obesity-related disorders, such as insulin resistance, diabetes mellitus, hypertension, and dyslipidemia (16) (17) (18) (19) . There is a correlation between inflammatory markers and VAT in nondiabetic nonpregnant people (5, 20) . Inflammatory markers such as CRP are associated with central obesity and in turn with increased risk for diabetes mellitus and cardiovascular disease (4, 5, 21, 22) . The reason behind the correlation between serum CRP concentrations and VAT is not understood very well, but it has been proposed that VAT is more active than SCFT with regard to cytokine synthesis (23) . Both VAT and SCFT are more strongly associated with CRP in women than in men (24) .
The most important point in our study is the study population, which consisted of pregnant women. Similar to nonpregnant population, we detected significantly high CRP and HbA1c levels in pregnant women with higher VAT and SCFT thicknesses. CRP and HbA1c levels were higher than normal by a significant proportion (45.5% and 18.2%) in subjects with VAT over 4 cm. In those with thicker SCFT (over 2 cm), CRP and HbA1c were higher than normal in 31.3% (10) and 18.8% (6) of cases, respectively. We think that the presence of VAT of ≥4 cm and/or SCFT of ≥2 cm is a very strong predictor of high CRP and HbA1c levels in pregnant women. Values of VAT and SCFT thickness that are significantly greater than the cut-off point in the first trimester might be associated with pregnancy-related complications observed during later gestation periods. Therefore, measurement of firsttrimester CRP and VAT and SCFT thicknesses over the cut-off point might help us to identify risk groups in whom early detection of gestational diabetes or hypertension is essential.
Another important point of our study was significantly high BMIs in women with VAT over 4 cm and/or SCFT over 2 cm. In pregnancy, the correct calculation of BMI might be difficult due to weight gain and fluid retention. However, VAT and SCFT can easily be measured in all pregnant women and they could correctly predict obesity and related complications during pregnancy.
CRP level is associated with BMI and waist circumference, which is a crude index of visceral obesity (4, 5) , but correct measurement of waist circumference may be difficult during pregnancy. Our study demonstrated that CRP and HbA1c were significantly higher in pregnant women with BMIs over 25 kg/m 2 than in women with normal BMIs. According to these results, VAT and/or SCFT thickness, CRP, and HbA1c levels could be evaluated in the first trimester in women with BMIs of ≥25 kg/m 2 . Another important result of this study was significantly high GGT levels in women with VAT over 4 cm. Serum GGT level is a possible marker of oxidative stress (25) . It is associated with development of metabolic syndrome and glucose intolerance (26) . It is suggested that GGT is associated with VAT, but not with SCFT, and a direct relationship between GGT and VAT exists in women (27, 28) . There is also a significant association between GGT and CRP levels (29, 30) . In this study, we detected high serum GGT in patients with high VAT thicknesses, although no correlation between GRP and CRP or SCFT was found. Our findings underscore the positive association of both VAT and SCFT with circulating markers of inflammation. Thus, an increase in VAT and/or SCFT relative to overall body weight is associated with significantly elevated CRP concentrations; this relation, which is most marked in women, is also observed in pregnant women. Our results were similar to the results of the Framingham Heart Study (13) . It suggested that both abdominal SCFT and VAT have a role in inflammation and oxidative stress. According to the results after adjustment for clinical measures of adiposity, only VAT remained associated with inflammatory markers while only SCFT remained associated with fibrinogen.
A number of limitations of this study deserve comment. First, although the sample size was adequate, study groups were quite modest in size, so it is possible that the study size was insufficient for detecting differences between all groups. Second, we only used CRP, HbA1c, and GGT as parameters for prediction of metabolic disorders. Other risk factors that can modify the condition also must be assessed separately. Third, the perinatal results of cases were not evaluated. Long-term follow-up of the cases and evaluation of perinatal results would be important to correctly stratify the future risk. We also did not exclude prenatal supplemental vitamin users from the study, even though inflammatory responses can change for women who use antioxidant vitamins.
In conclusion, serum levels of inflammatory markers were significantly higher in obese pregnant women than nonobese ones. In obese subjects (BMI ≥ 25), HbA1c, VAT, and SCFT thickness were also higher. HbA1c, CRP, and GGT were significantly correlated with BMI, VAT, and, to a lesser degree, SCFT. In addition to overall obesity, VAT thickness is the most important parameter responsible for low-grade chronic inflammation and insulin resistance in obese pregnant women. These findings suggest that decreasing obesity, and particularly VAT, may prevent pathologies caused by inflammation during pregnancy and lower the risk of future metabolic and cardiovascular disease.
